Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion

More like this

• Health09/23/2026@HealthDesk

  Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Starts 08/31/2026CONFIRMED88% CONFIDENCE23 days agoThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]

  Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.

  $2.9B

  0.72

  00
• Health09/23/2026@HealthDesk

  Lilly Submits Retatrutide to the FDA for Approval

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Starts 03/31/2027ESTIMATED3 months late77% CONFIDENCEin 189 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]

  Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.

  0.67

  00
• Health09/23/2026@HealthDesk

  Lilly Agrees to Acquire Centessa for Up to $7.8 Billion

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Starts 03/31/2026CONFIRMED87% CONFIDENCE176 days agoThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]

  Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.

  $7.8B

  0.67

  00
• Health09/23/2026@HealthDesk

  Eli Lilly Becomes the First Drugmaker Worth $1 Trillion

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Starts 11/21/2025CONFIRMED87% CONFIDENCE306 days agoBioPharma Dive^[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's^[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.

  Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.

  0.63

  00
• Health09/23/2026@HealthDesk

  Eli Lilly Q3 2026 Earnings Call

  Eli Lilly·…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

  Starts 10/29/2026 2:00PMESTIMATED71% CONFIDENCEin 36 daysLilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com^[2] and Nasdaq^[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.

  Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.

  0.62

  00
• Business09/23/2026@HealthDesk

  J&J Completes Its $1 Billion Acquisition of Firefly Bio

  South San Francisco, San Mateo County, California, United StatesJohnson & Johnson·…

  

  Starts 07/29/2026CONFIRMED87% CONFIDENCE56 days ago"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ^[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".

  Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.

  $1B

  0.62

  00
• Health09/23/2026@HealthDesk

  Lilly Breaks Ground on $6.5B Foundayo Plant in Houston's Generation Park

  Eli Lilly·…North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United States

  Starts 09/21/2026CONFIRMED84% CONFIDENCE2 days agoLilly's release is datelined "HOUSTON^[4], Sept. 21, 2026" and says Lilly "broke ground today in Houston, Texas^[6]"; Community Impact^[2] reports the groundbreaking ceremony was held Sept. 21.

  A 236-acre plant that will make the active ingredient of Lilly's Foundayo weight-loss pill, with more than 600 permanent jobs and about 4,000 construction jobs. Lilly expects it running by 2030.

  $6.5B

  0.60

  00
• Health09/20/2026@HealthDesk

  MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out

  Sanofi·…Paris, Grand Paris, France

  Starts 03/13/2028ESTIMATED50% CONFIDENCEin 1.5 yearsClinicalTrials.gov^[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m

  0.59

  00
• Health09/23/2026@HealthDesk

  FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer

  Eli Lilly·…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States

  Starts 09/18/2026CONFIRMED85% CONFIDENCE5 days agoLilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.

  An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.

  0.59

  00
• Health09/23/2026@HealthDesk

  Abbott Settles DOJ Infant Formula Claims for $385 Million

  Abbott Laboratories·…Sturgis, Saint Joseph County, Michigan, 49091, United States

  Starts 09/14/2026CONFIRMED88% CONFIDENCE9 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]

  Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.

  $385M

  0.58

  00
• Business09/23/2026@HealthDesk

  Apollo in Talks to Buy J&J's DePuy Synthes for About $20 Billion

  Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson·…

  

  Starts 09/11/2026CONFIRMED82% CONFIDENCE12 days agoThe disclosure is Bloomberg's report, dated "September 11, 2026" (Yahoo's^[1][2][5] syndicated copy went up at 22:26 UTC and quotes Friday's closing share prices); Reuters' write-up the same evening says "Bloomberg News reported on Friday", and Quartz's 14 September story is a follow-up, so the pin is the all-day 11 September.

  Bloomberg reported that Apollo Global Management is in talks to buy DePuy Synthes, J&J's $9.3 billion-a-year orthopaedics unit, at a value close to $20 billion, with a deal possible within weeks though J&J could still spin the unit off instead.

  $20B

  0.58

  00
• Health09/23/2026@HealthDesk

  J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx

  Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson·…

  

  Starts 01/08/2026CONFIRMED86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]

  Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.

  0.57

  00